Apraclonidine clinical trials
How each study uses apraclonidine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the apraclonidine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 31 Dec 1987 · IOPIDINE · NDA 019779 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2020 | 1 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 4
Alcon Research (2) · American University of Beirut Medical Center (1) · Retina Consultants of Delmarva (1) · Walter Reed Army Medical Center (1) · University of Alabama at Birmingham (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test apraclonidine.
- Dec 2026Iopidine to Decrease Intraocular Pressure Rise After InjectionsPhase 4 · Retina Consultants of Delmarva
Studies
Open first, then newest update. How each study uses apraclonidine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Iopidine to Decrease Intraocular Pressure Rise After InjectionsNot yet recruitingPhase 4Retina Consultants of DelmarvaNCT07891910Written as Apraclonidine 1.0% ophthalmic solutionHow we know
- An Investigation of FID 123320 for the Reduction of Ocular Redness in Pediatric and Adult PopulationsCompletedPhase 3Alcon ResearchNCT06538662Written as Apraclonidine Hydrochloride Ophthalmic SolutionHow we know
- A Double-Masked Comparison of FID 123320 Ophthalmic Solution to Vehicle for the Reduction of Ocular RednessCompletedPhase 3Alcon ResearchNCT06444529Written as Apraclonidine Hydrochloride Ophthalmic SolutionHow we know
- Efficacy of Topical Apraclonidine for the Treatment of Ocular SynkinesisWithdrawnPhase 4University of Alabama at BirminghamNCT05167760Written as ApraclonidineHow we know
- Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia GravisCompletedPhase 2American University of Beirut Medical CenterNCT05045248Written as Apraclonidine Hcl 0.5% Oph SolnHow we know
- Comparison of the Alpha-2 Agonists for Prevention of Intraocular Pressure Elevation After Selective Laser TrabeculoplastyStatus unknownNot applicableWalter Reed Army Medical CenterNCT00567411Written as Apraclonidine 0.5%How we know
What changed recently
From the registry's own updates since Oct 20, 2026.
Results posted2
Newly registered1
- Iopidine to Decrease Intraocular Pressure Rise After InjectionsOct 23, 2026NCT07891910
Codes
What other systems call apraclonidine · ClinicalTrials.gg INT002667
- MeSH (NLM) C016986apraclonidineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 843CEN85DIAPRACLONIDINEConfirmed FDA, NLM, Wikidata
- RxNorm 14845Confirmed FDA, Wikidata
- Wikidata Q4781812apraclonidineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C61640ApraclonidineOne source FDA
- DrugBank DB00964One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C016986 | apraclonidine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 843CEN85DI | APRACLONIDINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 14845 | — | Confirmed FDA, Wikidata |
| Wikidata | Q4781812 | apraclonidine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C61640 | Apraclonidine | One source FDA |
| DrugBank | DB00964 | — | One source Wikidata |
Also registered as apraclonidine hydrochloride (UNII D2VW67N38H · RxNorm 91350).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.